These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33277783)

  • 1. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States.
    Abell K; Chadwell SE; Burrow TA; Becker APP; Bailey L; Steele P; Zhang X; Islas-Ohlmayer M; Bittencourt R; Schwartz IVD; Prada CE
    Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1052-1059. PubMed ID: 33277783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
    Rosenbloom BE; Cappellini MD; Weinreb NJ; Dragosky M; Revel-Vilk S; Batista JL; Sekulic D; Mistry PK
    Am J Hematol; 2022 Oct; 97(10):1337-1347. PubMed ID: 36054609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
    Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
    El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
    Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of enzyme replacement therapy on gammopathies in Gaucher disease.
    Brautbar A; Elstein D; Pines G; Abrahamov A; Zimran A
    Blood Cells Mol Dis; 2004; 32(1):214-7. PubMed ID: 14757437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous multiple myeloma and Gaucher disease.
    Monge J; Chadburn A; Gergis U
    Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):42-45. PubMed ID: 31622574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
    Giuffrida G; Markovic U; Condorelli A; Duminuco A; Calafiore V; Conticello C; Romano A; Grasso S; Riccobene C; Ragusa MTV; Esposito B; Nicolosi D; Calagna M; Nardo A; Consoli U; Uccello G; Di Giacomo V; Neri S; Cingari MR; Rodà F; Innao V; Fiumara A; Duro G; Zizzo C; Di Raimondo F
    Eur J Haematol; 2023 Dec; 111(6):922-929. PubMed ID: 37747757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
    Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
    Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Gammopathies in a Fracture Liaison Service.
    McCall B; Ibrahim Z; Barth P; Aaron RK
    R I Med J (2013); 2022 Oct; 105(8):28-32. PubMed ID: 36173906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy.
    Nair S; Bar N; Xu ML; Dhodapkar M; Mistry PK
    Mol Genet Metab; 2020 Apr; 129(4):286-291. PubMed ID: 32044242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
    Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.